ArticleFrontiers in oncology2026
Exercise in regional breast cancer with neoadjuvant anthracycline-based chemotherapy with immune checkpoint-inhibition: study protocol for a prospective randomised controlled trial.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06672120 (Exercise in Regional Breast Cancer With Neoadjuvant Anthracycline- Based Chemotherapy and Immunotherapy With Checkpoint-Inhibition), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exercise in Regional Breast Cancer With Neoadjuvant Anthracycline- Based Chemotherapy and Immunotherapy With Checkpoint-Inhibition
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anthracycline-based chemotherapy and immune checkpoint inhibition-increasingly used together in triple negative breast cancer (BC)-both cause cardiotoxicity and decline in peak oxygen consumption (VO2peak). While guidelines recommend exercise training for BC, the effectiveness of endurance, strength, and balance training during neoadjuvant immunochemotherapy remains unclear. Methods: The ExACT-ICI (Exercise in Regional Breast Cancer with adjuvant and neoadjuvant Anthracycline-based ChemoTherapy with Immune Checkpoint-Inhibition, NCT06672120) trial is a prospective single-center study randomizing regional TNBC patients (stage I-III, ages 18-65) receiving anthracycline chemotherapy plus pembrolizumab into exercise training (ET) or usual care groups. ET participants complete five weekly video-supervised sessions (endurance, resistance, balance) during 24-week treatment, monitored via smartwatch. Both groups undergo cardiopulmonary exercise testing, stress echocardiography, and strength/balance assessments at baseline, 6, 12, and 24 weeks. The primary outcome is VO2peak change from baseline to 24 weeks, with secondary outcomes including physical function, cardiac biomarkers, echocardiographic variables, quality of life, strength, balance, and exploratory cardiac adverse events through 52 weeks. Discussion and limitations: This study is the first to assess the effects of exercise intervention on VO2peak during immunochemotherapy in TNBC patients. Repetitive testing and smart watch monitoring will ensure optimized exercise prescription and safety during supervised, video-based training sessions. The study is limited to patients able to participate in online training sessions with a digital device.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.